JP2010235616A - フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 - Google Patents
フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 Download PDFInfo
- Publication number
- JP2010235616A JP2010235616A JP2010115119A JP2010115119A JP2010235616A JP 2010235616 A JP2010235616 A JP 2010235616A JP 2010115119 A JP2010115119 A JP 2010115119A JP 2010115119 A JP2010115119 A JP 2010115119A JP 2010235616 A JP2010235616 A JP 2010235616A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- phytic acid
- same
- complex
- methyl donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 92
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 title claims abstract description 77
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 title claims abstract description 57
- 235000002949 phytic acid Nutrition 0.000 title claims abstract description 52
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims abstract description 50
- 229940068041 phytic acid Drugs 0.000 title claims abstract description 49
- 239000000467 phytic acid Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000015572 biosynthetic process Effects 0.000 title abstract description 18
- 238000003786 synthesis reaction Methods 0.000 title abstract description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 30
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims abstract description 22
- 150000001768 cations Chemical class 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 229910052751 metal Inorganic materials 0.000 claims abstract description 10
- 239000002184 metal Substances 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 15
- 150000004001 inositols Chemical class 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000002274 desiccant Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 239000001110 calcium chloride Substances 0.000 claims description 10
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 241000411851 herbal medicine Species 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 230000002443 hepatoprotective effect Effects 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 238000010981 drying operation Methods 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract description 18
- 229960000367 inositol Drugs 0.000 abstract description 18
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract description 18
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract description 17
- 229960003237 betaine Drugs 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 7
- 230000004071 biological effect Effects 0.000 abstract description 6
- 239000002676 xenobiotic agent Substances 0.000 abstract description 6
- 229930014626 natural product Natural products 0.000 abstract description 4
- 230000002034 xenobiotic effect Effects 0.000 abstract description 4
- 239000002417 nutraceutical Substances 0.000 abstract description 3
- 235000021436 nutraceutical agent Nutrition 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract description 2
- 239000000590 phytopharmaceutical Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 10
- XHJLCRULHISREH-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;sulfo hydrogen sulfate Chemical compound OS(=O)(=O)OS(O)(=O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 XHJLCRULHISREH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 8
- 229960001231 choline Drugs 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 108700003601 dimethylglycine Proteins 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- -1 other methyl donors Chemical compound 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006069 physical mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- QWARKYOPJRNOOU-RLUFNZFXSA-N [(3s)-3-amino-3-carboxypropyl]-[[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium;butane-1,4-disulfonate;butane-1,4-disulfonic acid Chemical compound OS(=O)(=O)CCCCS(O)(=O)=O.OS(=O)(=O)CCCCS(O)(=O)=O.[O-]S(=O)(=O)CCCCS([O-])(=O)=O.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QWARKYOPJRNOOU-RLUFNZFXSA-N 0.000 description 2
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- VERAMNDAEAQRGS-UHFFFAOYSA-N butane-1,4-disulfonic acid Chemical compound OS(=O)(=O)CCCCS(O)(=O)=O VERAMNDAEAQRGS-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940083982 sodium phytate Drugs 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KILDHTZVSDBCNT-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical compound S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(O)C1=CC=C(C)C=C1.S(=O)(=O)(O)C1=CC=C(C)C=C1.C1(=CC=C(C=C1)S(=O)(=O)O)C.C1(=CC=C(C=C1)S(=O)(=O)O)C.C1(=CC=C(C=C1)S(=O)(=O)O)C KILDHTZVSDBCNT-UHFFFAOYSA-N 0.000 description 1
- SQASAHFPWITLNX-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;sulfo hydrogen sulfate Chemical compound OS(=O)(=O)OS(O)(=O)=O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 SQASAHFPWITLNX-UHFFFAOYSA-N 0.000 description 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 241000134719 Aspergillus tamarii Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021148 Hypozincaemia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- QJPWUUJVYOJNMH-VKHMYHEASA-N L-homoserine lactone Chemical compound N[C@H]1CCOC1=O QJPWUUJVYOJNMH-VKHMYHEASA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 102000007357 Methionine adenosyltransferase Human genes 0.000 description 1
- 108010007784 Methionine adenosyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- HOXINJBQVZWYGZ-UHFFFAOYSA-N fenbutatin oxide Chemical compound C=1C=CC=CC=1C(C)(C)C[Sn](O[Sn](CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C1=CC=CC=C1 HOXINJBQVZWYGZ-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000006833 reintegration Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seasonings (AREA)
Abstract
【解決手段】本発明はメチル供与体の塩又はキレート、特にS−アデノシル−L−メチオニン即ちSAMe及びベタイン即ちN,N,N−トリメチルグリシンと、金属カチオンと任意選択で部分的に塩を形成していてもよい、フィチン酸又はリン酸化イノシトールとの塩又はキレートであって、元のメチル供与体特有の生物活性に更にフィチン酸又はイノシトール特有の生物活性と合わされ、それにより増強されている、安定で、全体に天然化合物を形成する塩又はキレートの製造法に関する。本発明はまた、フィチン酸若しくはその誘導体との、メチル供与体の1つ或いは複数の塩又は錯塩を含む、栄養補助、医薬、食物、生薬又は獣医学組成物及びその合成法に関する。
【選択図】なし
Description
これは天然、特に植物中に広く見出される化合物で、中でも特に脂肪種子、穀物及び豆類に豊富である。またフィチン酸そのものとして若しくはナトリウム塩(フィチン酸ナトリウム)の形で溶液で、又はカルシウム、マグネシウム混合塩[Ca5Mg(C6H6O24P6)]として市販されている。後者はフィチンと呼ばれ、リン酸化強壮剤及びカルシウム栄養補助食品として用いられる。
SAMe・n[(C6H(18−x)O24P6)・My/a・N(x−y)/b]
式中、SAMeはS−アデノシル−L−メチオニン分子であり、
nは1〜3の範囲の整数であり、
xは0〜12を含む数であり(0≦x≦12)、
yは0〜xを含む数であり(0≦y≦x)、
M及びNは一価又は多価の金属カチオンであり、
a及びbはそれぞれM及びNの酸化状態を示す。
mTMG・n[(C6H(18−x)O24P6)・My/a・N(x−y)/b]
式中、TMGはN,N,N−トリメチルグリシン分子であり、
m及びnは1〜10の範囲の整数であり、
xは0〜12を含む数であり(0≦x≦12)、
yは0〜xを含む数であり(0≦y≦x)、
M及びNは一価又は多価の金属カチオンであり、
a及びbはそれぞれM及びNの酸化状態を示す。
a)メチル供与化合物又はその塩を適当な溶媒に溶解する操作、
b)既定量のフィチン酸又はリン酸化イノシトールを添加する操作、
c)所望の塩又は錯塩が不溶である溶媒を反応混合物に添加する操作、
d)生成する沈殿物を集め、ろ過する操作、
e)前記沈殿物を乾燥又は放置により乾燥する操作。
SAMeフィチン酸塩の合成
下記の実施例において、イオン型のSAMeは発酵酵母から直接得られた。本発明による調製を、下記の手順により行った。
・SAMeイオン 1モル、
・フィチン 1モル、
・2/3滴の濃硫酸を添加する、
・3種の生成物を氷浴中で冷却、混合する、
・SAMeフィチン酸塩の沈殿が完全に得られるまでエタノールを添加する、
・ろ紙を用いて沈殿物をろ過後、塩化カルシウム又は無水リン酸を用いた乾燥器中に放置して乾燥する。
回収率>90%。
SAMe二硫酸トシル酸塩とフィチンの物理的混合物
先の実施例と同じ成分の、単純で、塩や錯塩を形成していない混合物の安定性を評価するために、フィチンとSAMe二硫酸トシル酸塩を同じ割合で単純に乾燥混合した(50%フィチン、50%SAMe二硫酸トシル酸塩)。
SAMeフィチン酸塩の合成
市販のSAMe塩であるSAMe二硫酸トシル酸塩を出発原料として、本発明による生成物の合成を下記の手順により行った。
1.400mgのSAMe二硫酸トシル酸塩を2.5mlの蒸留水に溶解する、
2.エーテル(5ml)中、p−トルエンスルホン酸(PTSA)を、分液ロートを用いて抽出する、
3.水層(PTSAを抽出後)に含まれている硫酸イオンを0.254mgの塩化バリウムで沈殿化後、4000rpmで5分間遠心分離(T=4℃)する、
4.上清にフィチン410mgの水懸濁液2.5mlをゆっくり添加(マグネチックスターラーで攪拌しながら)する、
5.2/3滴の硫酸を添加する、
6.氷浴中で10分間放置(溶液のpHは1.3)する、
7.20mlの95%エタノールを添加後、完全に沈殿が得られるまで氷浴中で放置する、極白色沈殿物が生成する、
8.沈殿物をろ紙上でろ過して分離(ポンプを使用した吸引ビン)する、
9.沈殿物を塩化カルシウム又は無水リン酸の存在下室温で乾燥し、24時間後、生成物は白色結晶性粉末となる。
フィチン酸とのSAMe塩の合成及び安定性評価
他の市販のSAMe塩であるSAMe1,4−ブタンジスルホン酸塩を出発原料として、本発明による生成物の合成を下記の手順により行った。
1.760mgのSAMe1,4−ブタンジスルホン酸塩を2ccの水に溶解する、
2.ステップ1の溶液に、直接4.95gの40%フィチン酸溶液を添加する、
3.氷浴中で1時間攪拌しながら放置する、
4.完全に沈殿が得られるまで95%エタノールを添加(氷浴中)する、
5.減圧ろ過する、
6.塩化カルシウム又は無水リン酸を用いた乾燥器中で24〜48時間乾燥する。
ステューデントt検定法により行った2群の平均%変動差には、高い有意差があったp<0.01。
フィチン酸とのベタイン塩の合成
N,N,N−トリメチルグリシン塩基(ベタイン)を出発原料として、本発明によるフィチン酸との錯塩を下記の手順で得た。
1.1.19gのベタイン塩基を2.5mlの蒸留水に溶解する、
2.1.65gの40%フィチン酸溶液を添加する、
3.溶液を室温で放置し、0.550gの塩化カルシウムを添加する、
4.25mlの95%エタノールを溶液に加え、全混合物を完全に沈殿が得られるまで4℃で放置する、
5.白色沈殿物をろ紙上でろ過することにより分離(吸引ビン)する、
6.沈殿物を適当な乾燥剤の存在下室温で乾燥し、24時間後、生成物は結晶性白色粉末様である。
Claims (15)
- S−アデノシル−L−メチオニン及びN,N,N−トリメチルグリシンからなる群から選択される、フィチン酸又はリン酸化イノシトールとのメチル供与化合物の塩又は錯塩であって、フィチン酸は、金属カチオンと塩を形成する1つ又は複数のリン酸基を有する、1つ又は複数の塩又は錯塩を含む、栄養補助、医薬、食物、生薬又は獣医学組成物。
- 前記メチル供与化合物がS−アデノシル−L−メチオニンであり、前記塩又は錯塩が請求項2に記載の通りである、請求項1記載の組成物。
- 前記メチル供与化合物がN,N,N−トリメチルグリシンであり、前記塩又は錯塩が請求項3に記載の通りである、請求項1記載の組成物。
- S−アデノシル−L−メチオニンの塩又は錯塩とN,N,N−トリメチルグリシンの塩又は錯塩との組合せを含む、請求項2又は3に記載の組成物。
- マイクロカプセル化された、請求項1〜4のいずれか一項に記載の組成物。
- S−アデノシル−L−メチオニン及びN,N,N−トリメチルグリシンからなる群から選択される、フィチン酸又はリン酸化イノシトールとのメチル供与化合物の塩又は錯塩であって、フィチン酸は、金属カチオンと塩を形成する1つ又は複数のリン酸基を有する、1つ又は複数の塩又は錯塩の、栄養補助、医薬、食物、生薬、化粧品又は獣医学製剤の製造への使用。
- 前記メチル供与化合物がS−アデノシル−L−メチオニンであり、前記塩又は錯塩が請求項2に記載の通りである、請求項6記載の使用。
- 前記メチル供与化合物がN,N,N−トリメチルグリシンであり、前記塩又は錯塩が請求項3に記載の通りである、請求項6記載の使用。
- 前記製剤が、抗うつ活性又はどのような場合でも中枢神経系に作用する製剤、肥満治療用製剤、リン栄養補助食品、カルシウム栄養補助食品及びマグネシウム栄養補助食品、肝保護製剤、皮膚科用活性を有する製剤並びに腫瘍活性を有する製剤からなる群から選択される、請求項6〜8のいずれか一項に記載の使用。
- S−アデノシル−L−メチオニン及びN,N,N−トリメチルグリシンからなる群から選択される、フィチン酸又はリン酸化イノシトールとのメチル供与化合物の塩又は錯塩であって、フィチン酸は、金属カチオンと塩を形成する1つ又は複数のリン酸基を有する、塩又は錯塩の製造方法であって、
a)メチル供与化合物又はその塩を適当な溶媒に溶解する操作と、
b)既定量のフィチン酸又はリン酸化イノシトールを添加する操作と、
c)所望の塩又は錯塩が不溶である溶媒を反応混合物に添加する操作と、
d)生成する沈殿物を集め、ろ過する操作と、
e)前記沈殿物を乾燥又は放置により乾燥する操作と、
を含む、方法。 - 前記メチル供与化合物がN,N,N−トリメチルグリシンであり、前記操作a)をN,N,N−トリメチルグリシン塩基を蒸留水に溶解することにより行い、前記操作b)の後、塩化カルシウム又は塩化マグネシウムを反応混合物に加え、前記操作c)において溶媒としてエタノールを加え、全混合物を完全に沈殿が得られるまで4℃で放置し、最後に前記操作e)を乾燥剤の存在下、室温で行う、請求項10記載の方法。
- 前記メチル供与化合物がS−アデノシル−L−メチオニン(SAMe)であり、前記操作a)をSAMe塩を蒸留水に溶解することにより行い、前記操作b)をフィチン酸を用いて行い、前記操作b)の後、反応混合物を氷浴中で攪拌しながら放置し、前記操作c)において溶媒としてエタノールを加え、全混合物を完全に沈殿が得られるまで氷浴中で放置し、最後に前記操作e)を乾燥剤の存在下で行う、請求項10記載の方法。
- 前記メチル供与化合物がS−アデノシル−L−メチオニン(SAMe)であり、前記操作a)をSAMe塩を蒸留水に溶解することにより行い、前記操作a)の後、SAMe塩に元来存在するアニオンを、適当な試薬を加えることにより塩として沈殿させ、前記操作b)をフィチンを加えることによって行い、前記操作b)の後、濃硫酸を加え、反応混合物を氷浴中で攪拌しながら放置、前記操作c)においてエタノールを加え、全混合物を完全に沈殿が得られるまで氷浴中で放置し、最後に前記操作e)を乾燥剤の存在下で行う、請求項10記載の方法。
- 前記乾燥剤が塩化カルシウム又は無水リン酸である請求項10〜13のいずれか一項に記載の方法。
- 前記乾燥操作e)の代わりに、前記沈殿物を噴霧乾燥又は凍結乾燥により乾燥する請求項10〜13のいずれか一項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2005A000344 | 2005-06-30 | ||
IT000344A ITRM20050344A1 (it) | 2005-06-30 | 2005-06-30 | Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519145A Division JP4589999B2 (ja) | 2005-06-30 | 2006-06-23 | フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010235616A true JP2010235616A (ja) | 2010-10-21 |
JP5283659B2 JP5283659B2 (ja) | 2013-09-04 |
Family
ID=39033793
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519145A Expired - Fee Related JP4589999B2 (ja) | 2005-06-30 | 2006-06-23 | フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 |
JP2010115119A Active JP5283659B2 (ja) | 2005-06-30 | 2010-05-19 | フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008519145A Expired - Fee Related JP4589999B2 (ja) | 2005-06-30 | 2006-06-23 | フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8293254B2 (ja) |
EP (1) | EP1896489B1 (ja) |
JP (2) | JP4589999B2 (ja) |
KR (1) | KR101346974B1 (ja) |
AT (1) | ATE419256T1 (ja) |
CY (1) | CY1108929T1 (ja) |
DE (1) | DE602006004588D1 (ja) |
DK (1) | DK1896489T3 (ja) |
ES (1) | ES2320489T3 (ja) |
IT (1) | ITRM20050344A1 (ja) |
PL (1) | PL1896489T3 (ja) |
PT (1) | PT1896489E (ja) |
SI (1) | SI1896489T1 (ja) |
WO (1) | WO2007004244A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011054375A1 (de) | 2010-10-20 | 2012-04-26 | Denso Corporation | Drehende elektrische Maschine für ein Fahrzeug |
JP2021046375A (ja) * | 2019-09-19 | 2021-03-25 | ポッカサッポロフード&ビバレッジ株式会社 | β3アドレナリン受容体活性化剤 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20060026A1 (it) * | 2006-01-10 | 2007-07-11 | Truffini & Regge Farmaceutici Srl | Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento |
ITMI20060629A1 (it) | 2006-03-31 | 2007-10-01 | Daniele Giovannone | Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento |
EP2039202B1 (en) | 2006-07-07 | 2017-12-13 | Telefonaktiebolaget LM Ericsson (publ) | Resource allocation for co-existin networks |
ITMI20071374A1 (it) * | 2007-07-10 | 2009-01-11 | Gnosis Spa | Sali stabili di s-adenosilmetionina e processo per il loro ottenimento. |
JP4598846B2 (ja) * | 2008-07-14 | 2010-12-15 | 磐田化学工業株式会社 | S−アデノシルメチオニン安定化のためのフィチン酸および/またはデキストリンを含む飲食用組成物 |
IT1393331B1 (it) * | 2009-02-09 | 2012-04-20 | Graal S R L | Composizioni orosolubili e/o effervescenti contenenti almeno un sale di s-adenosilmetionina (same) |
EP2945959B1 (en) * | 2013-01-16 | 2020-05-13 | Hebert Sam-E LLC | Stable indole-3-propionate salts of s-adenosyl-l-methionine |
ES2486441B1 (es) | 2014-04-02 | 2015-06-11 | Universitat De Les Illes Balears | Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico |
CA2995395C (en) | 2015-08-31 | 2024-04-16 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
IT201700074957A1 (it) * | 2017-07-04 | 2019-01-04 | Gnosis Spa | Sale di (ss)-adenosil metionina con inositolo esafosfato e procedimento per ottenerlo |
FR3068602B1 (fr) * | 2017-07-10 | 2020-11-20 | Guy Parc | Nouveau traitement du cancer par une combinaison d'un derive phosphorique d'inositol et de chlorure de magnesium |
CN115572309B (zh) * | 2022-09-20 | 2024-05-03 | 浙江工业大学 | 一种高效阻燃、抗熔滴的环境友好型阻燃剂 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2824869A (en) * | 1954-08-04 | 1958-02-25 | Bristol Lab Inc | Salt of streptomycin and phytic acid |
US3019226A (en) * | 1959-04-10 | 1962-01-30 | Olin Mathieson | Piperazine salt of phytic acid |
US3242235A (en) * | 1963-06-13 | 1966-03-22 | Squibb & Sons Inc | Phytate salts of the tetracyclines |
JPS5076215A (ja) * | 1973-06-27 | 1975-06-21 | ||
JPS61189293A (ja) * | 1985-02-14 | 1986-08-22 | ジビフアルマ・エツセ・ピ・ア | ポリアニオンとのsamの安定な塩、その製法および有効成分としてそれを含有する抗脂肝剤 |
JPH0215032A (ja) * | 1988-07-01 | 1990-01-18 | Sanwa Kagaku Kenkyusho Co Ltd | 肝疾患治療、予防剤及び強肝機能性飲食、し好物 |
JPH09509934A (ja) * | 1994-03-04 | 1997-10-07 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚シワを調節するために環状ポリアニオン系ポリオール誘導体を用いる方法 |
WO2002010177A1 (en) * | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
JP2002145783A (ja) * | 2000-11-06 | 2002-05-22 | Kohjin Co Ltd | S−アデノシルメチオニンまたはその塩類を含有するカプセル製剤 |
WO2003087109A1 (en) * | 2002-04-12 | 2003-10-23 | Silbiotec Due S.A. | Medicaments containing glycerophosphoinositol-4-phosphate derivatives |
JP2003534349A (ja) * | 2000-05-25 | 2003-11-18 | ケメンテクノ・エツセ・エルレ・エルレ | (ss,rs)−s−アデノシル−l−メチオニンの薬剤として許容される塩の調製方法 |
JP2003535126A (ja) * | 2000-06-02 | 2003-11-25 | ザ プロクター アンド ギャンブル カンパニー | 定義した健康上の利益を促進する組成物、キット、及び方法 |
US20060046982A1 (en) * | 2004-08-26 | 2006-03-02 | Waugh William H | Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease |
JP2008511544A (ja) * | 2004-08-12 | 2008-04-17 | クエスト ファーマシューティカル サーヴィシーズ | 生物活性化合物の制御放出送達用医薬組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030078231A1 (en) * | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
-
2005
- 2005-06-30 IT IT000344A patent/ITRM20050344A1/it unknown
-
2006
- 2006-06-23 JP JP2008519145A patent/JP4589999B2/ja not_active Expired - Fee Related
- 2006-06-23 US US11/923,000 patent/US8293254B2/en active Active
- 2006-06-23 WO PCT/IT2006/000484 patent/WO2007004244A1/en active Application Filing
- 2006-06-23 AT AT06766355T patent/ATE419256T1/de active
- 2006-06-23 ES ES06766355T patent/ES2320489T3/es active Active
- 2006-06-23 KR KR1020087001591A patent/KR101346974B1/ko active IP Right Grant
- 2006-06-23 EP EP06766355A patent/EP1896489B1/en active Active
- 2006-06-23 SI SI200630246T patent/SI1896489T1/sl unknown
- 2006-06-23 DE DE602006004588T patent/DE602006004588D1/de active Active
- 2006-06-23 PT PT06766355T patent/PT1896489E/pt unknown
- 2006-06-23 PL PL06766355T patent/PL1896489T3/pl unknown
- 2006-06-23 DK DK06766355T patent/DK1896489T3/da active
-
2009
- 2009-03-26 CY CY20091100356T patent/CY1108929T1/el unknown
-
2010
- 2010-05-19 JP JP2010115119A patent/JP5283659B2/ja active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2824869A (en) * | 1954-08-04 | 1958-02-25 | Bristol Lab Inc | Salt of streptomycin and phytic acid |
US3019226A (en) * | 1959-04-10 | 1962-01-30 | Olin Mathieson | Piperazine salt of phytic acid |
US3242235A (en) * | 1963-06-13 | 1966-03-22 | Squibb & Sons Inc | Phytate salts of the tetracyclines |
JPS5076215A (ja) * | 1973-06-27 | 1975-06-21 | ||
JPS61189293A (ja) * | 1985-02-14 | 1986-08-22 | ジビフアルマ・エツセ・ピ・ア | ポリアニオンとのsamの安定な塩、その製法および有効成分としてそれを含有する抗脂肝剤 |
JPH0215032A (ja) * | 1988-07-01 | 1990-01-18 | Sanwa Kagaku Kenkyusho Co Ltd | 肝疾患治療、予防剤及び強肝機能性飲食、し好物 |
JPH09509934A (ja) * | 1994-03-04 | 1997-10-07 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚シワを調節するために環状ポリアニオン系ポリオール誘導体を用いる方法 |
JP2003534349A (ja) * | 2000-05-25 | 2003-11-18 | ケメンテクノ・エツセ・エルレ・エルレ | (ss,rs)−s−アデノシル−l−メチオニンの薬剤として許容される塩の調製方法 |
JP2003535126A (ja) * | 2000-06-02 | 2003-11-25 | ザ プロクター アンド ギャンブル カンパニー | 定義した健康上の利益を促進する組成物、キット、及び方法 |
WO2002010177A1 (en) * | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
JP2002145783A (ja) * | 2000-11-06 | 2002-05-22 | Kohjin Co Ltd | S−アデノシルメチオニンまたはその塩類を含有するカプセル製剤 |
WO2003087109A1 (en) * | 2002-04-12 | 2003-10-23 | Silbiotec Due S.A. | Medicaments containing glycerophosphoinositol-4-phosphate derivatives |
JP2008511544A (ja) * | 2004-08-12 | 2008-04-17 | クエスト ファーマシューティカル サーヴィシーズ | 生物活性化合物の制御放出送達用医薬組成物 |
US20060046982A1 (en) * | 2004-08-26 | 2006-03-02 | Waugh William H | Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease |
Non-Patent Citations (3)
Title |
---|
JPN7012004048; イタリア国特許第1043885号明細書 * |
JPN7012004049; イタリア国特許第1054175号 * |
JPN7012004050; 「SAM-e supereSSe (スーパーエッセ)」 , (株式会社オムニカ) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011054375A1 (de) | 2010-10-20 | 2012-04-26 | Denso Corporation | Drehende elektrische Maschine für ein Fahrzeug |
JP2021046375A (ja) * | 2019-09-19 | 2021-03-25 | ポッカサッポロフード&ビバレッジ株式会社 | β3アドレナリン受容体活性化剤 |
Also Published As
Publication number | Publication date |
---|---|
SI1896489T1 (sl) | 2009-06-30 |
EP1896489A1 (en) | 2008-03-12 |
ITRM20050344A1 (it) | 2007-01-01 |
DE602006004588D1 (de) | 2009-02-12 |
ES2320489T3 (es) | 2009-05-22 |
US20090175914A1 (en) | 2009-07-09 |
KR20080028949A (ko) | 2008-04-02 |
JP5283659B2 (ja) | 2013-09-04 |
JP2009500319A (ja) | 2009-01-08 |
EP1896489B1 (en) | 2008-12-31 |
ATE419256T1 (de) | 2009-01-15 |
KR101346974B1 (ko) | 2014-01-02 |
DK1896489T3 (da) | 2009-04-20 |
WO2007004244A1 (en) | 2007-01-11 |
JP4589999B2 (ja) | 2010-12-01 |
PL1896489T3 (pl) | 2009-06-30 |
US8293254B2 (en) | 2012-10-23 |
PT1896489E (pt) | 2009-04-01 |
CY1108929T1 (el) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4589999B2 (ja) | フィチン酸又はその誘導体とのメチル供与体の塩又は錯塩、及びその合成法 | |
CN111902053A (zh) | 溶血磷脂酰胆碱组合物 | |
US6806069B2 (en) | Ubiquinone composition and methods related thereto | |
US9597308B2 (en) | N-acetyl L-cysteine chelates and methods for making and using the same | |
JP2005525335A (ja) | N−アシル−ホスファチジル−エタノールアミン類及び/又はn−アシル−エタノールアミン類とホスファチジン酸類又はリゾホスファチジン酸類との混合物 | |
MXPA04003255A (es) | Utilizacion de acido hidrocioleico y compuestos analogos del mismo en la fabricacion de medicamentos. | |
US20070009590A1 (en) | Physiologically active composition based on phosphatidylserine | |
CN1460102A (zh) | 营养和疗效增强的肌酸盐及含有该盐的组合物 | |
CZ20023949A3 (cs) | Fumarát karnitinu a aminokyseliny a potravinové a dietetní doplňky a léčiva je obsahující | |
KR20060088090A (ko) | 인체 내 고밀도 콜레스테롤 함량을 증가시키는 건강 기능성계란 | |
CA2922396C (en) | N-acetyl l-cysteine chelates and methods for making and using the same | |
US20180214463A1 (en) | Use of phytic acid or the salts thereof, alone or combined with b6 vitamers, for preventing the formation of advanced glycation end-product | |
WO2022224776A1 (ja) | 脂質減少促進剤 | |
JP2011524415A (ja) | L−カルニチンフィチン酸塩及びアルカノイル−l−カルニチンフィチン酸塩と、その製造方法 | |
JP5227579B2 (ja) | 食後インスリン上昇抑制剤 | |
RU2266683C1 (ru) | Способ увеличения биологической ценности продуктов питания | |
Ito et al. | Antitumor effect of 6-phenyl-7 (6H)-isoselenazolo [4, 3-d] pyrimidone on the growth of Ehrlich ascites tumor | |
US8067468B2 (en) | L-carnitine and alkanoyl L-carnitine phytates and process for preparing the same | |
AU2022381752A1 (en) | Ketone precursors and methods therefor | |
WO2014010742A1 (ja) | モノガラクトシルジアシルグリセロール又はその薬学的に許容し得る塩を有効成分として含む医薬組成物又は食品組成物 | |
ZA200300639B (en) | Pharmaceuticals and nutritional supplements. | |
Orekhova et al. | Biologically active nonlipid derivatives of MYO-inositol and prospects for their use in drug design (a review) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130131 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130402 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130517 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130528 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5283659 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |